Literature DB >> 8964650

Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A.

J O Funk1, M Ernst, M M Schönharting, P Zabel.   

Abstract

The methylxanthine derivative pentoxifylline (PTX) is an immunomodulatory agent with incompletely characterized effects on cytokine production. To analyse these effects and to delineate new combination strategies in immunotherapy, we have investigated immunomodulatory properties of PTX in combination with dexamethasone (DEX) or cyclosporin A (CsA). Stimulated human peripheral blood mononuclear cells were treated with clinically relevant concentrations of PTX (12.5-100 micrograms/ml), DEX (0.01-10 microM) or CsA (12.5-50 ng/ml), alone or in combination. With increasing doses of PTX the maximum supernatant titres of tumour necrosis factor (TNF)-alpha, interleukin (IL)-2 and interferon (IFN)-gamma decreased concomitantly, and all cultures co-treated with DEX showed synergism. Release of IL-6 was not consistently altered under PTX treatment. Similarly, PTX and CsA synergistically inhibited the release of IL-2, IFN-gamma and, to a lesser degree, TNF-alpha. Although PTX alone did not significantly reduce lymphoproliferation, both combinations of drugs synergistically inhibited this process. Furthermore, to demonstrate that the key mechanism of PTX-induced effects is an increase in intracellular cyclic adenosine 3':5'-monophosphate (cAMP) levels, identical experiments were performed using dibutyryl-cAMP instead of PTX. In cultures treated with PTX and DEX, expression of different cell receptors was analysed. Expression of IL-2 receptor (IL-2R) was reduced in cultures treated with PTX, and combination with DEX led to further reduction. Expression of intercellular adhesion molecule (ICAM)-1 and of leucocyte function antigen (LFA)-1 alpha was also synergistically reduced, though to a lesser degree. HLA-DR expression remained unchanged. In conclusion, we demonstrate that clinically relevant levels of PTX exert profound immunomodulatory effects in vitro, and that the combined treatment with DEX or CsA has synergistic effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8964650     DOI: 10.1016/0192-0561(95)00096-8

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  7 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

Review 2.  Evaluation of current therapeutic strategies in Behçet's disease.

Authors:  Iliana Alexoudi; Violetta Kapsimali; Aristides Vaiopoulos; Meletios Kanakis; George Vaiopoulos
Journal:  Clin Rheumatol       Date:  2010-09-15       Impact factor: 2.980

3.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

4.  Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury.

Authors:  Jin-Moo Lee; Ping Yan; Qingli Xiao; Shawei Chen; Kuang-Yung Lee; Chung Y Hsu; Jan Xu
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

5.  Pentoxifylline and Methylprednisolone Additively Alleviate Kidney Failure and Prolong Survival of Rats after Renal Warm Ischemia-Reperfusion.

Authors:  Grzegorz Wystrychowski; Wojciech Wystrychowski; Władysław Grzeszczak; Andrzej Więcek; Robert Król; Antoni Wystrychowski
Journal:  Int J Mol Sci       Date:  2018-01-11       Impact factor: 5.923

6.  Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro.

Authors:  Esther M Speer; David J Dowling; Jianjin Xu; Lukasz S Ozog; Jaime A Mathew; Avinash Chander; Donglei Yin; Ofer Levy
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

7.  Effects of pentoxifylline on whole blood IL-2 and IFN-gamma gene expression in normal dogs.

Authors:  Evangel Kummari; Andres Gibbs; Caitlin Riggs; Claire Fellman; John Stokes; John Thomason; Robert Wills; Andrew Mackin; Todd Archer
Journal:  Vet Med Sci       Date:  2019-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.